Salivary Soluble CD44: A Molecular Marker for Head and *

描述(由申请人提供)： 头颈部鳞状细胞癌(HNSCC)在全世界约有500,000例癌症发生。HNSCC的治疗是手术、放疗和化疗的组合，通常会导致显著的发病率和高昂的医疗费用。消除最初的肿瘤提供了最好的治愈机会，但我们只有50%的机会成功。治疗失败最常见的原因是原发灶或颈部复发，较少发生远处转移。如果能及早发现初发或复发的肿瘤，治疗结果会更好。不幸的是，大多数HNSCC是在后期发现的。能够在早期阶段发现新的癌症和复发的HNSCC标志物将是有用的。CD44在其他组织中可能是恶性的分子标志物，并且在体液中以可溶性形式被检测到(SolCD44)。我们的初步数据表明，与对照组相比，HNSCC患者唾液中solCD44的表达增加。在这项研究中，我们将检测solCD44在新诊断的HNSCC患者和对照组中的表达，以及在HNSCC复发或二次原发病例中的表达。我们将使用solCD44酶联免疫吸附试验和蛋白检测来评估HNSCC患者唾液中solCD44的表达(目标1)。我们将把这些指标与年龄、性别、种族、社会经济地位、烟草和酒精使用情况相匹配的对照组的Sol CD44水平进行比较。我们将使用相同的方法来评估复发或第二次初次HNSCC匹配的患者中solCD44的表达，这些患者既往治疗、初始阶段、烟草和酒精使用(目标2)。这些研究的结果将决定soICD44酶联免疫吸附试验作为筛查HNSCC的有效性。

DESCRIPTION (provided by applicant): Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 500,000 incident cancers worldwide. The treatment of HNSCC, combinations of surgery, radiation and chemotherapy, often result in significant morbidity and substantial healthcare costs. Elimination of the initial tumor offers the best chance of cure, yet we succeed only 50 percent of the time. Therapy fails most often due to recurrence at the primary site or in the neck, and less often from distant metastases. When initial or recurrent tumors are identified early, treatment outcome is better. Unfortunately the majority of HNSCC are identified in later stage. A marker for HNSCC that is able to detect new cancers and recurrences in early stages would be useful. CD44 may be a molecular marker of malignancy in other tissues and is detectable in body fluids in soluble form (solCD44). Our preliminary data suggest that solCD44 is increased in the saliva of HNSCC tumor patients compared to controls. In this study we will examine the expression of solCD44 in both newly diagnosed HNSCC patients and controls and in HNSCC patients with recurrence or second primaries. We will use a solCD44 ELISA test and a protein assay to evaluate the expression of solCD44 in HNSCC patient's saliva (aim 1). We will compare these to sol CD44 levels in controls that are matched for age, sex, race, socioeconomic status, tobacco and alcohol use. We will use the same assays to evaluate the expression of solCD44 in patients with recurrent or second primary HNSCC matching for previous treatment, original stage, tobacco and alcohol use (aim 2). The results of these studies will determine the validity of soICD44 ELISA test as a screening test for HNSCC.